Radiofrequency ablation of liver tumors: The role of microbubble ultrasound contrast agents

Maria Franca Meloni, Tito Livraghi, Carlo Filice, Sergio Lazzaroni, Fabrizio Calliada, Leonardo Perretti

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Radiofrequency ablation (RFA) is currently indicated for the treatment of primary and metastatic hepatic malignancies. Real-time ultrasound (US) is generally used during the procedure to guide electrode placement, but for evaluating the results of treatment, contrast-enhanced computed tomography and magnetic resonance imaging have traditionally been considered more effective. This view has changed, however, with the recent development of contrast-enhanced ultrasound (CEUS) (eg, using sulfur hexafluoride microbubbles), which can provide valuable information on the effects of RFA more rapidly and economically than computed tomography or magnetic resonance imaging without exposing the patient to ionizing radiation. In our center, CEUS is performed in patients with liver tumors before and immediately after RFA, in selected cases during the procedure as well, and in the follow-up. Between January 2003 and June 2005, we performed CEUS on 350 patients scheduled for RFA of primary or metastatic liver tumors. In 14 (13.4%) of the 96 patients whose disease was metastatic, CEUS revealed lesions that had been missed on the conventional US examination. In most of these cases, the result was a more complete treatment performed under CEUS guidance. In the remaining 2 (14%) of 14, the results of the examination allowed us to avoid subjecting the patient to useless treatment. In our experience, the use of CEUS also improved the management and follow-up of patients undergoing interstitial therapy.

Original languageEnglish
Pages (from-to)41-47
Number of pages7
JournalUltrasound Quarterly
Volume22
Issue number1
Publication statusPublished - Mar 2006

Fingerprint

Microbubbles
Contrast Media
Liver
Neoplasms
Sulfur Hexafluoride
Tomography
Magnetic Resonance Imaging
Therapeutics
Ionizing Radiation
Electrodes

Keywords

  • Contrast-enhanced ultrasound
  • Hepatocellular carcinoma
  • Liver tumors
  • Metastases
  • Radiofrequency tumor ablation

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Radiofrequency ablation of liver tumors : The role of microbubble ultrasound contrast agents. / Meloni, Maria Franca; Livraghi, Tito; Filice, Carlo; Lazzaroni, Sergio; Calliada, Fabrizio; Perretti, Leonardo.

In: Ultrasound Quarterly, Vol. 22, No. 1, 03.2006, p. 41-47.

Research output: Contribution to journalArticle

Meloni, MF, Livraghi, T, Filice, C, Lazzaroni, S, Calliada, F & Perretti, L 2006, 'Radiofrequency ablation of liver tumors: The role of microbubble ultrasound contrast agents', Ultrasound Quarterly, vol. 22, no. 1, pp. 41-47.
Meloni, Maria Franca ; Livraghi, Tito ; Filice, Carlo ; Lazzaroni, Sergio ; Calliada, Fabrizio ; Perretti, Leonardo. / Radiofrequency ablation of liver tumors : The role of microbubble ultrasound contrast agents. In: Ultrasound Quarterly. 2006 ; Vol. 22, No. 1. pp. 41-47.
@article{995da859c61b4623bf67f391ea9d7317,
title = "Radiofrequency ablation of liver tumors: The role of microbubble ultrasound contrast agents",
abstract = "Radiofrequency ablation (RFA) is currently indicated for the treatment of primary and metastatic hepatic malignancies. Real-time ultrasound (US) is generally used during the procedure to guide electrode placement, but for evaluating the results of treatment, contrast-enhanced computed tomography and magnetic resonance imaging have traditionally been considered more effective. This view has changed, however, with the recent development of contrast-enhanced ultrasound (CEUS) (eg, using sulfur hexafluoride microbubbles), which can provide valuable information on the effects of RFA more rapidly and economically than computed tomography or magnetic resonance imaging without exposing the patient to ionizing radiation. In our center, CEUS is performed in patients with liver tumors before and immediately after RFA, in selected cases during the procedure as well, and in the follow-up. Between January 2003 and June 2005, we performed CEUS on 350 patients scheduled for RFA of primary or metastatic liver tumors. In 14 (13.4{\%}) of the 96 patients whose disease was metastatic, CEUS revealed lesions that had been missed on the conventional US examination. In most of these cases, the result was a more complete treatment performed under CEUS guidance. In the remaining 2 (14{\%}) of 14, the results of the examination allowed us to avoid subjecting the patient to useless treatment. In our experience, the use of CEUS also improved the management and follow-up of patients undergoing interstitial therapy.",
keywords = "Contrast-enhanced ultrasound, Hepatocellular carcinoma, Liver tumors, Metastases, Radiofrequency tumor ablation",
author = "Meloni, {Maria Franca} and Tito Livraghi and Carlo Filice and Sergio Lazzaroni and Fabrizio Calliada and Leonardo Perretti",
year = "2006",
month = "3",
language = "English",
volume = "22",
pages = "41--47",
journal = "Ultrasound Quarterly",
issn = "0894-8771",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Radiofrequency ablation of liver tumors

T2 - The role of microbubble ultrasound contrast agents

AU - Meloni, Maria Franca

AU - Livraghi, Tito

AU - Filice, Carlo

AU - Lazzaroni, Sergio

AU - Calliada, Fabrizio

AU - Perretti, Leonardo

PY - 2006/3

Y1 - 2006/3

N2 - Radiofrequency ablation (RFA) is currently indicated for the treatment of primary and metastatic hepatic malignancies. Real-time ultrasound (US) is generally used during the procedure to guide electrode placement, but for evaluating the results of treatment, contrast-enhanced computed tomography and magnetic resonance imaging have traditionally been considered more effective. This view has changed, however, with the recent development of contrast-enhanced ultrasound (CEUS) (eg, using sulfur hexafluoride microbubbles), which can provide valuable information on the effects of RFA more rapidly and economically than computed tomography or magnetic resonance imaging without exposing the patient to ionizing radiation. In our center, CEUS is performed in patients with liver tumors before and immediately after RFA, in selected cases during the procedure as well, and in the follow-up. Between January 2003 and June 2005, we performed CEUS on 350 patients scheduled for RFA of primary or metastatic liver tumors. In 14 (13.4%) of the 96 patients whose disease was metastatic, CEUS revealed lesions that had been missed on the conventional US examination. In most of these cases, the result was a more complete treatment performed under CEUS guidance. In the remaining 2 (14%) of 14, the results of the examination allowed us to avoid subjecting the patient to useless treatment. In our experience, the use of CEUS also improved the management and follow-up of patients undergoing interstitial therapy.

AB - Radiofrequency ablation (RFA) is currently indicated for the treatment of primary and metastatic hepatic malignancies. Real-time ultrasound (US) is generally used during the procedure to guide electrode placement, but for evaluating the results of treatment, contrast-enhanced computed tomography and magnetic resonance imaging have traditionally been considered more effective. This view has changed, however, with the recent development of contrast-enhanced ultrasound (CEUS) (eg, using sulfur hexafluoride microbubbles), which can provide valuable information on the effects of RFA more rapidly and economically than computed tomography or magnetic resonance imaging without exposing the patient to ionizing radiation. In our center, CEUS is performed in patients with liver tumors before and immediately after RFA, in selected cases during the procedure as well, and in the follow-up. Between January 2003 and June 2005, we performed CEUS on 350 patients scheduled for RFA of primary or metastatic liver tumors. In 14 (13.4%) of the 96 patients whose disease was metastatic, CEUS revealed lesions that had been missed on the conventional US examination. In most of these cases, the result was a more complete treatment performed under CEUS guidance. In the remaining 2 (14%) of 14, the results of the examination allowed us to avoid subjecting the patient to useless treatment. In our experience, the use of CEUS also improved the management and follow-up of patients undergoing interstitial therapy.

KW - Contrast-enhanced ultrasound

KW - Hepatocellular carcinoma

KW - Liver tumors

KW - Metastases

KW - Radiofrequency tumor ablation

UR - http://www.scopus.com/inward/record.url?scp=33749439156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749439156&partnerID=8YFLogxK

M3 - Article

C2 - 16641792

AN - SCOPUS:33749439156

VL - 22

SP - 41

EP - 47

JO - Ultrasound Quarterly

JF - Ultrasound Quarterly

SN - 0894-8771

IS - 1

ER -